Results 41 to 50 of about 694 (96)

Medication guide for dose adjustment and management of cardiotoxicity and lipid metabolic adverse events of oral antineoplastic therapy

Frontiers in Oncology, 2023
ObjectiveThe management of cardiotoxicity concerning the use of oral antineoplastic agents (OAAs) is a challenge for healthcare professionals. Our objective was to create a comprehensive medication management guide with dose adjustment recommendations on
Elena Ramos-Ruperez, Vicente Escudero-Vilaplana, Vicente Escudero-Vilaplana, Paula Ruiz-Briones, Paula Ruiz-Briones, Roberto Collado-Borrell, Roberto Collado-Borrell, Cristina Villanueva-Bueno, Cristina Villanueva-Bueno, José Luis Revuelta-Herrero, José Luis Revuelta-Herrero, Eva González-Haba, Eva González-Haba, Xandra Garcia-Gonzalez, Xandra Garcia-Gonzalez, Sara Ibañez-Garcia, Sara Ibañez-Garcia, Sara Perez-Ramirez, Sara Perez-Ramirez, Eduardo Zatarain-Nicolás, Eduardo Zatarain-Nicolás, Eduardo Zatarain-Nicolás, Eduardo Zatarain-Nicolás, Ana Herranz, Ana Herranz, María Sanjurjo, María Sanjurjo   +26 more
doaj   +1 more source

Targeting the translational machinery in gastrointestinal stromal tumors (GIST): a new therapeutic vulnerability

Scientific Reports, 2022
Although KIT-mutant GISTs can be effectively treated with tyrosine kinase inhibitors (TKIs), many patients develop resistance to imatinib mesylate (IM) as well as the FDA-approved later-line agents sunitinib, regorafenib and ripretinib.
Donna M. Lee, Angela Sun, Sneha S. Patil, Lijun Liu, Aparna V. Rao, Parker T. Trent, Areej A. Ali, Catherine Liu, Jessica L. Rausch, Laura D. Presutti, Adam Kaczorowski, Felix Schneider, Nduka M. Amankulor, Masahiro Shuda, Anette Duensing   +14 more
doaj   +1 more source

Progression in treatment of advanced gastrointestinal stromal tumors [PDF]

Waike lilun yu shijian
Gain-of-function mutations in KIT or PDGFRA receptor tyrosine kinase are key drivers of most gastrointestinal stromal tumor (GIST). The continuous development of tyrosine kinase inhibitors, such as imatinib, sunitinib, anlotinib, regorafenib, ripretinib ...
TANG Haixiao, ZHANG Yun, HAN Gang, GONG Hangjun
doaj   +1 more source

Recent advances in drug therapy for advanced gastrointestinal stromal tumor

Zhongguo aizheng zazhi, 2021
Gastrointestinal stromal tumors (GISTs) are rare neoplasms of the gastrointestinal tract associated with high rates of malignant transformation. Tyrosine kinase inhibitors (TKIs) as targeted agents are the backbone for advanced GIST treatment. During the
汪　明, 曹　晖
doaj  

Why precision oncology works: lessons from gastrointestinal stromal tumours [PDF]

Exploration of Targeted Anti-tumor Therapy
Gastrointestinal stromal tumours (GISTs) are the clearest solid-tumour model of precision oncology because diagnosis, prognosis, and treatment are strongly shaped by molecular genotype. The discovery of activating mutations in KIT proto-oncogene receptor
Si Ying Adelina Ho, Alwyn Hong Sheng Tok, Hui Qi Megan Kimberly Han, Jens Samol, Vishal G Shelat   +4 more
doaj   +1 more source

Systemic mastocytosis, in the context of a deleterious germline SDHC variant, treated with ripretinib

JAAD Case Reports, 2023
Sara Saheb Kashaf, MPhil, Lucy A. Godley, MD, PhD, Angad Chadha, MD, Jason B. Waldinger, MD   +3 more
doaj   +1 more source

Single-center clinico-genomic analysis of KIT mutated melanomas and clinical outcomes with tyrosine kinase inhibitor treatment

EJC Skin Cancer
Background: KIT alterations occur in distinct melanoma subtypes, yet KIT-mutant melanoma remains clinically and biologically heterogeneous and lacks approved KIT-targeted therapy.
Carl Maximilian Thielmann, Luisa Richter, Henry Karl Tapken, Johanna Andrea Seier, Lisa Schielke, Jan Sternberg, Julia Kretz, Inga Möller, Antje Sucker, Annette Paschen, Lennart Ocker-Serger, Frederik Krefting, Anne Zaremba, Lea Jessica Albrecht, Lisa Zimmer, Elisabeth Livingstone, Georg Lodde, Alpaslan Tasdogan, Jan-Malte Placke, Eva Hadaschik, Florian Rambow, Sebastian Bauer, Andrea Forschner, Dirk Schadendorf, Philipp Jansen, Klaus Griewank   +25 more
doaj   +1 more source

Corrigendum: Compassionate use of ripretinib for patients with metastatic gastrointestinal stromal tumors: Taiwan and Hong Kong experience

Frontiers in Oncology, 2022
Li-Ching Lin, Wen-Kuan Huang, Chueh-Chuan Yen, Chueh-Chuan Yen, Ching-Yao Yang, Meng-Ta Sung, Natalie S.M. Wong, Daniel T. T. Chua, Sarah W. M. Lee, Jen-Shi Chen, Chun-Nan Yeh   +10 more
doaj   +1 more source

The Effect of Yinchenhao Decoction on the Pharmacokinetic Profile of Futibatinib by HPLC-MS/MS

Separations
Futibatinib is an excellent fibroblast growth factor receptor 1–4 (FGFR 1–4) inhibitor that exhibits selective anti-tumor activeness against FGFR-deregulated tumors.
Chunfu Wang, Songmao Liang, Jiachen Xu, Yingfan Zhai, Jianghui Chen, Xiangjun Qiu   +5 more
doaj   +1 more source

Emerging mechanisms of kinase inhibitor escape and clinical implications of ponatinib in advanced gastrointestinal stromal tumor. [PDF]

J Gastrointest Oncol
Shenoy S.
europepmc   +1 more source